CMS-121

• Description :

  CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities[1][2][3].

• UNSPSC :

  12352005

• Target :

  Acetyl-CoA Carboxylase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/cms-121.html

• Purity :

  99.63

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  OC1=CC=C(C2=NC3=CC=CC=C3C(OC4CCCC4)=C2)C=C1O

• Molecular Formula :

  C20H19NO3

• Molecular Weight :

  321.37

• References & Citations :

  [1]Currais A, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. Elife. 2019 Nov 19;8. pii: e47866.|[2]Chiruta C, et al. Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem. 2012 Jan 12;55 (1) :378-89.|[3]Prior M, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014 Jul 16;5 (7) :503-13.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [1353224-53-9]